References
- Chobanian AV, Bakris GL, Black HR, Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42(6):1206–1252.
- Japanese Society of Hypertension. Guidelines for the management of hypertension (JSH 2004). Hypertens Res Aug 2006;29 (suppl):S1–105.
- Mancia G, De Backer G, Dominiczak A, 2007 Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25(6):1105–1187.
- Pitt B, Zannad F, Remme WJ, The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 1999;341(10):709–717.
- Gumieniak O, Williams GH. Mineralocorticoid receptor antagonists and hypertension: Is there a rationale? Curr Hypertens Rep 2004;6(4):279–287.
- Ouzan J, Perault C, Lincoff AM, The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002;15(4 Pt 1):333–339.
- Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003;16(11 Pt 1):925–930.
- Mancia G, De Backer G, Dominiczak A, 2007 Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28(12):1462–1536.
- Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci 2002;970:89–100.
- Sato A, Saruta T. Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens 2003;16(9 Pt 1):781–788.
- Arima S. Aldosterone and the kidney: Rapid regulation of renal microcirculation. Steroids 2006;71(4):281–285.
- Kasama S, Toyama T, Sumino H, Additive effects of spironolactone and candesartan on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure. J Nucl Med 2007;48(12):1993–2000.
- Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: A meta-analysis. Lancet 20 2001;358(9290):1305–1315.
- Juurlink DN, Mamdani MM, Lee DS, Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004;351(6):543–551.
- Pitt B, Remme W, Zannad F, Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348(14):1309–1321.
- Sato A, Hayashi K, Naruse M, Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003;41(1):64–68.
- Ogawa S, Takeuchi K, Mori T, Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor. Clin Exp Pharmacol Physiol 2006;33(5–6):477–479.
- Sato A, Suzuki Y, Saruta T. Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension. Hypertens Res 1999;22(1):17–22.
- Chapman N, Dobson J, Wilson S, Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007;49(4):839–845.
- Williams B, Poulter NR, Brown MJ, British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): Summary. BMJ 2004;328(7440):634–640.